Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to firstname.lastname@example.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 16 October 2015 | By Michael Mezher
In a letter dated Wednesday, US Food and Drug Administration (FDA) Commissioner nominee Robert Califf endorsed an internal report detailing recommendations for how FDA could improve reviews of combination products, but says that the agency is already in the midst of addressing the issues called out in the report.
Combination products, or any products combining drugs, devices, and biologicals, create complex regulatory challenges for both FDA and their sponsors.
In 2002, in order to better coordinate the review of combination products, FDA created a set of procedures for intercenter consults. These consults are intended to improve the "timeliness and consistency" of FDA staff "when requesting, receiving, handling, processing, and tracking formal consultative and collaborative reviews."
In 2014, after an industry survey highlighted concerns over communication and coordination issues during Intercenter consults for combination products, FDA's Office of Planning (OPL) launched a study into coordination and communication at the agency.
Specifically, the study aimed to look into "management, timing, timeliness, and workload challenges" related to intercenter consults.
To conduct the study, FDA staff asked two industry groups, the Combination Products Coalition (CPC) and the Advanced Medical Technology Association (AdvaMed), for input on the issues industry faces from intercenter consults.
After receiving input from industry, the study team held a series of focus groups with staff from two of its centers, the Center for Devices and Radiological Health (CDRH) and the Center for Drug Evaluation and Research (CDER). Afterward, the study team conducted 18 interviews with FDA staff ranging from those in "leadership positions [and] in key roles related to combination product review."
After reviewing the data gathered during the discussions and interviews, the study team identified four issues:
After considering the major issues brought up during the discussions with industry and FDA stakeholders, the study team issued five recommendations for the agency to undertake to "improve the overall efficiency, consistency, and predictability" of combination product reviews:
After thanking OPL for its assessment and recommendations and stating his office's commitment to "effective, efficient, transparent, and consistent regulation," Califf asserts that the agency is already making strides towards many of the recommendations.
In the letter, Califf claims that the Centers, the Office of Special Medical Programs and Office of Combination Products have already made efforts "consistent with report recommendations" to the first four recommendations and says that more improvements "will be coming this year and next."
Intercenter Consult Process Study (With Letter), FDA Voice, Combination Products Coalition Recommendations
Tags: Combination products, Intercenter consults